All News
Filter News
Found 199 articles
-
2 Biotechs Face Key Decisions in Mid-Fourth Quarter
10/21/2016
-
ProQR Therapeutics B.V. Announces Clinical Data Presentations And Investor & Analyst Event At NACFC
9/27/2016
-
ProQR Therapeutics B.V. To Present At Scientific And Investor Conferences In September
9/6/2016
-
ProQR Therapeutics B.V. Announces Results For The Second Quarter Of 2016
8/17/2016
-
ProQR Therapeutics B.V. Receives Fast Track Designation From FDA For QR-010 For Cystic Fibrosis
7/19/2016
-
ProQR Therapeutics B.V. To Release Topline Data From Proof Of Concept Study Of QR-010 In Cystic Fibrosis Patients At NACFC
6/21/2016
-
ProQR Therapeutics B.V.’s Drug Candidate QR-110 For Leber’s Congenital Amaurosis Type 10 Receives European Medicines Agency And FDA Orphan Drug Designation
6/1/2016
-
ProQR Therapeutics B.V. Announces Presentations At The European CF Conference And The JMP Life Science Conference
6/1/2016
-
ProQR Therapeutics B.V. Announces Results For The First Quarter Of 2016
5/18/2016
-
ProQR Therapeutics B.V. Announces Annual Meeting Of Shareholders
4/7/2016
-
ProQR Therapeutics B.V. To Highlight A Growing Pipeline During A Research & Development Day And Present At The Barclays Global Healthcare Conference
3/1/2016
-
ProQR Therapeutics B.V. Announces Results For The Fourth Quarter And Full Year 2015
2/17/2016
-
ProQR Therapeutics B.V. To Present At The Leerink Partners Global Healthcare Conference
2/3/2016
-
ProQR Therapeutics B.V. Announces R&D Day And Provides Update On Innovation Portfolio
11/30/2015
-
ProQR Therapeutics B.V. Announces Results For The Third Quarter Of 2015 And Provides Update On Clinical Trials
11/23/2015
-
ProQR Therapeutics B.V. An Investor And Analyst Event And Pre-Clinical Data Presentations For QR-010 For Cystic Fibrosis At Two Upcoming Scientific Conferences
10/1/2015
-
ProQR Therapeutics B.V. To Present At The Leerink Partners 4th Annual Rare Disease Roundtable
9/23/2015
-
Former Genzyme CEO Henri Termeer Leads $10 Million Series B for Autoimmune Company Artax Biopharma
9/22/2015
-
ProQR Therapeutics B.V. Announces A Proof-Of-Concept Nasal Potential Difference Study Of QR-010 Is Open For Enrollment
9/14/2015
-
ProQR Therapeutics B.V. Announces Results For The Second Quarter Of 2015
8/19/2015